|
|
Prepublished online as a Blood First Edition Paper on March 20, 2003; DOI 10.1182/blood-2002-11-3390.
 Previous Article | Table of Contents | Next Article 
Blood, 15 July 2003, Vol. 102, No. 2, pp. 489-496
GENE THERAPY
Genetically targeted radiotherapy for multiple myeloma
David Dingli,
Rosa Maria Diaz,
Elizabeth R. Bergert,
Michael K. O'Connor,
John C. Morris, and
Stephen J. Russell
From the Molecular Medicine Program, the Division of Hematology, the Division of Endocrinology and Metabolism, and the Department of Radiology, Mayo Clinic and Foundation, Rochester, MN.
Multiple myeloma is a disseminated neoplasm of terminally differentiated plasma cells that is incurable with currently available therapies. Although the disease is radiosensitive, external beam radiation leads to significant toxicity due to sensitive end-organ damage. Thus, genetic approaches for therapy are required. We hypothesized that the incorporation of immunoglobulin promoter and enhancer elements in a self-inactivating (SIN) lentiviral vector should lead to specific and high-level transgene expression in myeloma cells. A SIN lentivector with enhanced green fluorescent protein (EGFP) expression under the control of a minimal immunoglobulin promoter as well as the Kappa light chain intronic and 3' enhancers transduced myeloma cell lines with high efficiency (30%-90%). EGFP was expressed at a high level in myeloma cells but silent in all nonmyeloma cell lines tested compared with the cytomegalovirus (CMV) promoter/enhancer. Transduction of myeloma cells with the targeted vector coding for the human sodiumiodide symporter (hNIS) led to hNIS expression by these cells allowing them to concentrate radioiodine up to 18-fold compared with controls. Tumor xenografts in severe combined immunodeficiency mice expressing hNIS could be imaged using iodine-123 (123I) and shown to retain iodide for up to 48 hours. These tumor xenografts were completely eradicated by a single dose of the therapeutic isotope iodine-131 (131I) without evidence of recurrence up to 5 months after therapy. We conclude that lentivectors can be transcriptionally targeted for myeloma cells and the use of hNIS as a therapeutic gene for myeloma in combination with 131I needs further exploration.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. Hakkarainen, M. Rajecki, M. Sarparanta, M. Tenhunen, A. J. Airaksinen, R. A. Desmond, K. Kairemo, and A. Hemminki
Targeted Radiotherapy for Prostate Cancer with an Oncolytic Adenovirus Coding for Human Sodium Iodide Symporter
Clin. Cancer Res.,
September 1, 2009;
15(17):
5396 - 5403.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. K. Carlson, K. L. Classic, E. M. Hadac, D. Dingli, C. E. Bender, B. J. Kemp, and S. J. Russell
Quantitative Molecular Imaging of Viral Therapy for Pancreatic Cancer Using an Engineered Measles Virus Expressing the Sodium-Iodide Symporter Reporter Gene
Am. J. Roentgenol.,
January 1, 2009;
192(1):
279 - 287.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.-S. LIU, Y.-J. HSIEH, C.-C. KE, F.-D. CHEN, L. HWU, F.-H. WANG, J.-J. HWANG, C.-W. CHI, C.-H. LEE, and S.-H. YEH
Specific Activation of Sodium Iodide Symporter Gene in Hepatoma Using Alpha-fetoprotein Promoter Combined with Hepatitis B Virus Enhancer (EIIAPA)
Anticancer Res,
January 1, 2009;
29(1):
211 - 221.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Goel, S. K. Carlson, K. L. Classic, S. Greiner, S. Naik, A. T. Power, J. C. Bell, and S. J. Russell
Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV({Delta}51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene
Blood,
October 1, 2007;
110(7):
2342 - 2350.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Riesco-Eizaguirre and P. Santisteban
A perspective view of sodium iodide symporter research and its clinical implications.
Eur. J. Endocrinol.,
October 1, 2006;
155(4):
495 - 512.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T Kogai, K Taki, and G A Brent
Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.
Endocr. Relat. Cancer,
September 1, 2006;
13(3):
797 - 826.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Dohan, A. De la Vieja, and N. Carrasco
Hydrocortisone and Purinergic Signaling Stimulate Sodium/Iodide Symporter (NIS)-Mediated Iodide Transport in Breast Cancer Cells
Mol. Endocrinol.,
May 1, 2006;
20(5):
1121 - 1137.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Petrich, L. Quintanilla-Martinez, Z. Korkmaz, E. Samson, H. J. Helmeke, G. J. Meyer, W. H. Knapp, and E. Potter
Effective Cancer Therapy with the {alpha}-Particle Emitter [211At]Astatine in a Mouse Model of Genetically Modified Sodium/Iodide Symporter-Expressing Tumors
Clin. Cancer Res.,
February 15, 2006;
12(4):
1342 - 1348.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Cengic, C. H. Baker, M. Schutz, B. Goke, J. C. Morris, and C. Spitzweg
A Novel Therapeutic Strategy for Medullary Thyroid Cancer Based on Radioiodine Therapy following Tissue-Specific Sodium Iodide Symporter Gene Expression
J. Clin. Endocrinol. Metab.,
August 1, 2005;
90(8):
4457 - 4464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Mitrofanova, R. Unfer, N. Vahanian, W. Daniels, E. Roberson, T. Seregina, P. Seth, and C. Link Jr.
Rat Sodium Iodide Symporter for Radioiodide Therapy of Cancer
Clin. Cancer Res.,
October 15, 2004;
10(20):
6969 - 6976.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Dingli, K.-W. Peng, M. E. Harvey, P. R. Greipp, M. K. O'Connor, R. Cattaneo, J. C. Morris, and S. J. Russell
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter
Blood,
March 1, 2004;
103(5):
1641 - 1646.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Russell and K.-W. Peng
Primer on Medical Genomics Part X: Gene Therapy
Mayo Clin. Proc.,
November 1, 2003;
78(11):
1370 - 1383.
[Abstract]
[PDF]
|
|
|
|
|
